Animal Nutrition & Health

FUMzyme®

dsm-firmenich PERFORMANCE SOLUTIONS

The first-ever FDA-approved purified enzyme to degrade fumonisins in swine and poultry feed

FUMzyme® is the first-ever FDA-approved purified enzyme to specifically and irreversibly degrade fumonisins (FUM) into non-toxic metabolites.  Patented and scientifically-proven deactivation of fumonisins, FUMzyme® helps swine & poultry producers reduce the negative impact of mycotoxins and protect the value of their feed.

Looking for more information?

Our experts are always available to help.

If you are an existing customer, please go directly to our Customer Portal.

Main benefits

  • Specific and irreversible degradation of fumonisins into non-toxic metabolites 
  • Scientifically-proven deactivation of fumonisins 
  • Helps producers reduce the negative impact of mycotoxins and protect the value of their feed
Detoxification reaction

FUMzyme® biotransformation of fumonisin B1 into non-toxic metabolites

Why do we need an enzyme against fumonisins?

Fumonisins, a class of mycotoxins found in corn and other feed ingredients, is the second most prevalent group of mycotoxins worldwide.  Since 2014, Fumonisins have been detected in 50 to 80% of the US corn samples screened as part of the dsm-firmenich Mycotoxin Survey. Fumonisins can interact with other mycotoxins and have synergistic effects that impair health and productivity of livestock and poultry.

Unlike aflatoxins, fumonisins cannot be sufficiently bound by “binders” at the relevant pH along the gastrointestinal tract. The figure to the right demonstrates the pH-dependent adsorption of fumonisin by different binders on the market:

The figure demonstrates the pH dependency of adsorption of fumonisin by different binders on the market

In vitro and in vivo efficacy

The detoxifying activity of this revolutionary enzyme was confirmed by in vitro and in vivo experiments. 

In vivo efficacy - Piglets

In vivo efficacy - Broilers

Products

FUMzyme® is available as part of the Biofix® product portfolio:

Share